<DOC>
	<DOCNO>NCT01291394</DOCNO>
	<brief_summary>This National , Multicentre , Observational Registry study adherence long term outcome therapy paediatric subject use Easypod™ electromechanical device growth hormone treatment hospital France ass level adherence subject receive SAIZEN® via Easypod™ .</brief_summary>
	<brief_title>To Assess Level Adherence Subjects Receiving SAIZEN® Via Easypod™ France</brief_title>
	<detailed_description>Subjects enrol observational , multi-center study assess adherence treatment outcome . Parents provide write agreement upload child 's data study electronic CRF . Easypod™ electromechanical device delivers growth hormone also record injection ' date time . Adherence data primarily derive injection record Easypod™ device combine physician data entry outcome measure ( i.e . height &amp; weight ) . This allow establishment adherence profile evaluate link subsequent clinical outcome . Since observational study , study-specific clinical intervention subject treat accord clinical laboratory finding routinely evaluate physician . Auxological laboratory data report prospectively throughout duration study . At baseline , available data record retrospectively subject ' medical file Easypod™ device Data collect retrospectively prospectively . This allow establishment adherence profile subsequent clinical outcome . Collected data also analyze multinational pooled analysis comparable national study . Primary Objective : • To assess level adherence subject receive Saizen® via Easypod™ Secondary Objectives : - To describe impact adherence clinical outcome subject receive Saizen® via Easypod™ - To identify adherence subject profile - To asses Impact adherence insulin-like growth factor-1 ( IGF1 ) ranges/levels</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Administered Saizen® via Easypod™ electromechanical device accord pediatric registered indication ( Growth Hormone Deficiency , Small Gestational Age , TurnerSyndrome prepubertal child Chronic Renal Failure ) . Naïve subject already treat Saizen Easypod maximum 1 year Male Female 2 18 year age , 18 without fusion growth plat Parent 's guardian 's ( subject 18 without fusion growth plat ) write agreement , give enter data study , understand subject parent/guardian may withdraw agreement time without prejudice future medical care . Subjects take Saizen® growth plate fuse ( i.e . take growth hormone 's metabolic effect ) Contraindications Saizen® define French Summary Product Characteristics ( SmPC ) Use investigational drug participation interventional clinical study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Growth disorder</keyword>
	<keyword>Saizen</keyword>
	<keyword>Easypod</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Pediatric subject</keyword>
</DOC>